Companies › Andover Research Eye Institute
2 active drug programs in 2 registered trials: 2 Phase 4; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Preservative Free Polyethylene glycol 400 0.25% | – | Phase 4 | Dry Eye Disease (DED) | Dec 2026 |
| Propylene Glycol | – | Phase 4 | Dry Eye Disease (DED) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07676084 | Preservative Free Polyethylene glycol 400 0.25% | Phase 4 | Dry Eye Disease (DED) | Ophthalmology | Dec 2026 |
| NCT07676084 | Propylene Glycol | Phase 4 | Dry Eye Disease (DED) | Ophthalmology | Dec 2026 |
No annotated target.
–
SANGMYUNG innovation Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.